Angiotensin II receptor blockade and skeletal muscle metabolism in overweight and obese adults with elevated blood pressure | Zendy

Nabil E. Boutagy | Zendy; Elaina L. Marinik | Zendy; Ryan P. McMillan | Zendy; Angela S. Anderson | Zendy; Madlyn I. Frisard | Zendy; Brenda M. Davy | Zendy; Jose M. Rivero | Zendy; Kevin P. Davy | Zendy; Matthew W. Hulver | Zendy

Open Access

Angiotensin II receptor blockade and skeletal muscle metabolism in overweight and obese adults with elevated blood pressure

Author(s) -

Nabil E. Boutagy,

Elaina L. Marinik,

Ryan P. McMillan,

Angela S. Anderson,

Madlyn I. Frisard,

Brenda M. Davy,

Jose M. Rivero,

Kevin P. Davy,

Matthew W. Hulver

Publication year - 2015

Publication title -

therapeutic advances in cardiovascular disease

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.164

H-Index - 33

eISSN - 1753-9455

pISSN - 1753-9447

DOI - 10.1177/1753944714566426

Subject(s) - olmesartan , endocrinology , medicine , skeletal muscle , beta oxidation , angiotensin ii , angiotensin receptor , blood pressure , metabolism

Whether angiotensin II receptor blockade improves skeletal muscle fatty acid oxidation in overweight and obese humans is unknown. The purpose of the study was to test the hypothesis that the angiotensin II receptor blocker, olmesartan, would increase fatty acid oxidation and the activity of enzymes associated with oxidative metabolism in skeletal muscle of overweight and obese humans.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research